US Appln. No.: 10/553069 US Filing Date: 10/12/2005 Case No.: 21170P Page No.: 2

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

Claim 1. (original) Form B montelukast sodium characterized as having an x-ray powder diffraction pattern peak position substantially as shown:

2 θ	d spacing (A)	Intensity
5.4	16.4	s
5.7	15.6	vs
9.5	9.3	m
10.4	8.5	m
17.1	5.2	S
18.7	4.73	S
21.6	4.11	S

Claims 2-7. Canceled

Claim 8. (original) Montelukast sodium:acetonitrile monosolvate.

Claim 9. (previously presented) Montelukast sodium:acetonitrile monosolvate of Claim 8 characterized by having <sup>13</sup>C solid-state CPMAS NMR chemical shifts in ppm at 72 (sharp triplet), 74 (sharp triplet), 77 (sharp triplet), 179 (sharp doublet), and 182 (sharp doublet).

Claim 10. (original) Montelukast sodium:acetonitrile monosolvate of Claim 8 further characterized by having X-ray powder diffraction peaks substantially as shown:

2 θ	d spacing (Å)	Intensity
4.30	20.5	vs
5.9	14.9	S
6.2	14.3	S

US Appln. No.: 10/553069 US Filing Date: 10/12/2005 Case No.: 21170P Page No.: 3

6.8	13.0	W
7.3	12.0	W
10.5	8.4	m
11.0	8.0	W
12.7	7.0	m
16.2	5.5	S
18.1	4.90	W
18.7	4.74	W
21.6	4.12	W
23.4	3.80	W
23.9	3.72	W

Claim 11. (original) Monteclukast sodium:acetonitrile hemisolvate.

Claim 12. (original) Montelukast sodium:acetonitrile hemisolvate of Claim 10 characterized by having <sup>13</sup>C solid-state CPMAS NMR chemical shifts in ppm at 27 (well resolved) and 55 (well resolved), referenced by setting the carbonyl resonance of glycine to 176.08.

Claim 13. (original) Montelukast sodium:acetonitrile hemisolvate of Claim 10 characterized by having X-ray powder diffraction peaks substantially as shown:

2 θ	d spacing (Å)	Intensity
4.57	19.3	S
5.3	16.7	s
5.6	15.7	vs
6.5	13.6	m
9.4	9.4	m
10.3	8.6	w
11.6	7.6	m
14.1	6.3	w
14.5	6.1	m
15.1	5.8	W
16.2	5.5	m
17.0	5.2	m
18.5	4.79	s
20.8	4.26	m

US Appln. No.: 10/553069 US Filing Date: 10/12/2005 Case No.: 21170P Page No.: 4

21.3	4.17	S

Claim 14. (original) A method for the preparation of montelukast sodium Form A substantially free of amorphous montelukast sodium comprising: 1) collecting montelukast sodium:acetonitrile monosolvate; and 2) removing acetonitrile from the collected monosolvate.

Claim 15. (original) A method for the preparation of montelukast sodium Form A substantially free of amorphous montelukast sodium comprising: 1) contacting amorphous montelukast sodium or a mixture of amorphous montelukast sodium and montelukast sodium Form A with acetonitrile to form montelukast sodium:acetonitrile monosolvate; 2) collecting said monosolvate; and 3) removing acetonitrile from the collected monosolvate.

Claim 16. (original) The method of Claim 14 wherein a mixture of amorphous montelukast sodium and montelukast sodium Form A is used in step 1).